X-Chem Licenses Second Drug Discovery Program to Bayer

X-Chem, Inc. has licensed a second drug discovery program to Bayer Pharma AG under a multi-target collaboration established in July 2012. The latest program includes a series of small molecule compounds against a cardiovascular drug target. X-Chem will receive an upfront license fee in addition to preclinical, clinical, sales milestones, as well as royalties. The financial terms were not disclosed.
 
“This license further validates the innovative nature of X-Chem’s team and approach,” said Prof. Dr. Hanno Wild, senior vice president and head of Candidate Generation & Exploration at Bayer HealthCare Global Drug Discovery. “We look forward to continuing our collaboration with X-Chem.”
 
“We were delighted to work with Bayer on a cardiovascular program which is particularly challenging from a drug discovery perspective,” said Rick Wagner, Ph.D., chief executive officer of X-Chem. “X-Chem has built its library and discovery engine to meet the challenges of such highly difficult targets and promote the discovery of multiple chemical series directly out of our primary screens.”